|
|
Article: MedImmune Gaining Antibodies Through Cellective Acquisition.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
A year after raising $27 million in its Series A round, Cellective Therapeutics Inc. is being acquired by its larger neighbor, MedImmune Inc.
The move might be somewhat of a surprise, since privately held Cellective wasn't seeking a merger or acquisition and wasn't in need of additional financing, said Arthur Mandell, Cellective's CEO. But, he said, "MedImmune was able to recognize the value of what we were doing, and approached us."
Though specific financial terms were not disclosed, MedImmune agreed to purchase all outstanding common stock, pay a "sizable" up-front fee, and provide certain Cellective shareholders milestone ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|